Investor webinar
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes
Alderley Park, UK - 26 March 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that Dr Huw Jones, Chief Executive Officer, and Dr Alastair Smith, Non-executive Chair, will be hosting an investor webinar on Wednesday, 2 April 2025 at 6.00 pm (BST).
The webinar is open to all existing and potential investors and will focus on the Company's plans to drive its Ox-1 addiction and SFX-01 glioblastoma programmes, following the fundraise which completed earlier this month. These funds will enable the Company to take the Orexin-1 antagonist to the key inflection point of clinical trial readiness, allowing it to unlock potential commercial opportunities.
There will be a Q&A session after the presentation and questions can be pre-submitted as part of the registration process. You can register for the event for free at:
The webinar will be chaired by experienced news and corporate events presenter, Katie Pilbeam and hosted by TheraCryf's joint broker, Turner Pope Investments.
A more detailed presentation about Orexin-1, the market opportunity and the science behind the programme will be held in May.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.